Literature DB >> 23764727

Reduced cerebral arterial spin-labeled perfusion in children with neurofibromatosis type 1.

K W Yeom1, R M Lober, P D Barnes, C J Campen.   

Abstract

BACKGROUND AND
PURPOSE: Neurofibromatosis type 1 is associated with increased risk for stroke, cerebral vasculopathy, and neurocognitive deficits, but underlying hemodynamic changes in asymptomatic children remain poorly understood. We hypothesized that children with neurofibromatosis type 1 have decreased cerebral blood flow.
MATERIALS AND METHODS: Arterial spin-labeled CBF was measured in 14 children with neurofibromatosis type 1 (median age, 9.7 years; mean, 10.2 years; range, 22 months to 18 years) and compared with age-matched control subjects on 3T MR imaging. Three-dimensional pseudocontinuous spin-echo arterial spin-labeled technique was used. Measurements were obtained at cortical gray matter of bilateral cerebral hemispheres and centrum semiovale by use of the ROI method. Comparison by Mann-Whitney test was used, with Bonferroni-adjusted P values ≤.004 judged as significant.
RESULTS: We identified 7 of 12 areas with significantly diminished arterial spin-labeled CBF in patients with neurofibromatosis type 1 compared with control subjects. These areas included the anterior cingulate gyrus (P = .001), medial frontal cortex (P = .004), centrum semiovale (P = .004), temporo-occipital cortex (P = .002), thalamus (P = .001), posterior cingulate gyrus (P = .002), and occipital cortex (P = .001). Among patients with neurofibromatosis type 1, there were no significant differences in these regions on the basis of the presence of neurofibromatosis type 1 spots or neurocognitive deficits.
CONCLUSIONS: Reduced cerebral perfusion was seen in children with neurofibromatosis type 1, particularly in the posterior circulation and the vascular borderzones of the middle and posterior cerebral arteries.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764727      PMCID: PMC7965645          DOI: 10.3174/ajnr.A3649

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  40 in total

1.  Moyamoya disease in a child with neurofibromatosis type-1.

Authors:  K L Kwong; Y C Wong
Journal:  J Paediatr Child Health       Date:  1999-02       Impact factor: 1.954

2.  Development of MRI T2 hyperintensities and cognitive functioning in patients with neurofibromatosis type 1.

Authors:  Reinhold Feldmann; Gerhard Schuierer; Astrid Wessel; Nina Neveling; Josef Weglage
Journal:  Acta Paediatr       Date:  2010-11       Impact factor: 2.299

3.  A general kinetic model for quantitative perfusion imaging with arterial spin labeling.

Authors:  R B Buxton; L R Frank; E C Wong; B Siewert; S Warach; R R Edelman
Journal:  Magn Reson Med       Date:  1998-09       Impact factor: 4.668

Review 4.  Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force.

Authors:  K N North; V Riccardi; C Samango-Sprouse; R Ferner; B Moore; E Legius; N Ratner; M B Denckla
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

5.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

6.  Cerebral circulation in acute arterial hypertension--protective effects of sympathetic nervous activity.

Authors:  M Beausang-Linder; A Bill
Journal:  Acta Physiol Scand       Date:  1981-02

7.  Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T and comparison with 15O-water PET in elderly subjects at risk for Alzheimer's disease.

Authors:  Guofan Xu; Howard A Rowley; Gaohong Wu; David C Alsop; Ajit Shankaranarayanan; Maritza Dowling; Bradley T Christian; Terrence R Oakes; Sterling C Johnson
Journal:  NMR Biomed       Date:  2010-04       Impact factor: 4.044

8.  Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities.

Authors:  K North; P Joy; D Yuille; N Cocks; E Mobbs; P Hutchins; K McHugh; M de Silva
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

9.  Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication.

Authors:  J C Baron; P Lebrun-Grandie; P Collard; C Crouzel; G Mestelan; M G Bousser
Journal:  J Nucl Med       Date:  1982-05       Impact factor: 10.057

10.  Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET.

Authors:  P Balestri; G Lucignani; A Fois; L Magliani; L Calistri; C Grana; R M Di Bartolo; D Perani; F Fazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-12       Impact factor: 10.154

View more
  5 in total

1.  Gray Matter Growth Is Accompanied by Increasing Blood Flow and Decreasing Apparent Diffusion Coefficient during Childhood.

Authors:  N D Forkert; M D Li; R M Lober; K W Yeom
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-21       Impact factor: 3.825

2.  Arterial Transit Awesomeness.

Authors:  Greg Zaharchuk
Journal:  Radiology       Date:  2020-10-13       Impact factor: 29.146

3.  Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.

Authors:  Natalie R Boonzaier; Patrick W Hales; Felice D'Arco; Bronwen C Walters; Ramneek Kaur; Kshitij Mankad; Jessica Cooper; Alki Liasis; Victoria Smith; Patricia O'Hare; Darren Hargrave; Christopher A Clark
Journal:  Neuroimage Clin       Date:  2020-09-28       Impact factor: 4.881

Review 4.  The Genetic Basis of Strokes in Pediatric Populations and Insight into New Therapeutic Options.

Authors:  Milena Jankovic; Bojana Petrovic; Ivana Novakovic; Slavko Brankovic; Natasa Radosavljevic; Dejan Nikolic
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

5.  Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).

Authors:  Stavros Stivaros; Shruti Garg; Jonathan Green; Maria Tziraki; Ying Cai; Owen Thomas; Joseph Mellor; Andrew A Morris; Carly Jim; Karolina Szumanska-Ryt; Laura M Parkes; Hamied A Haroon; Daniela Montaldi; Nicholas Webb; John Keane; Francisco X Castellanos; Alcino J Silva; Sue Huson; Stephen Williams; D Gareth Evans; Richard Emsley
Journal:  Mol Autism       Date:  2018-02-22       Impact factor: 7.509

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.